Table 2.
Summary of clinical data of 50 patients
| Demographics | Total cohort(n = 50) | |
|---|---|---|
| Characteristic | n | (%) |
| Sex | ||
| Female | 22 | (44.0%) |
| Male | 28 | (56.0%) |
| Age at seizure onset | ||
| <1y | 43 | (86.0%) |
| ≥ 1y | 7 | (14.0%) |
| Cluster seizures | ||
| Yes | 28 | (56.0%) |
| No | 22 | (44.0%) |
| Positive family history | ||
| Yes | 16 | (32.0%) |
| No | 34 | (68.0%) |
| Dravet syndrome | ||
| Yes | 16 | (32.0%) |
| No | 34 | (68.0%) |
| Fever of first seizure | ||
| Yes | 32 | (64.0%) |
| No | 18 | (36.0%) |
| Thermal sensitivity | ||
| Yes | 43 | (86.0%) |
| No | 7 | (14.0%) |
| Status epilepticus | ||
| Yes | 18 | (36.0%) |
| No | 32 | (64.0%) |
| Developmental delay | ||
| Yes | 34 | (68.0%) |
| No | 16 | (32.0%) |
| EEG background slows down | ||
| Yes | 19 | (38.0%) |
| No | 31 | (62.0%) |
| Epilepsy first year EEG | ||
| Abnormal | 24 | (48.0%) |
| Normal | 26 | (52.0%) |
| Ketogenic diet | ||
| Effective | 4 | (80.0%) |
| No effect | 1 | (20.0%) |
| ASMs | ||
| No drugs | 1 | (2.0%) |
| Single drug | 12 | (24.0%) |
| Two kinds | 15 | (30.0%) |
| ≥ 3 kinds | 22 | (44.0%) |
| Therapeutic response | ||
| Seizure reduction ≥ 50% | 38 | (76.0%) |
| Seizure reduction<50% | 12 | (24.0%) |